Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 06/14/24 06:02:00 on US and Canada Markets.
2024-06-14 06:02:00 ET Why New Investors Should Look Into Investing in Penny Stocks Penny stocks offer an intriguing entry point for new investors looking to tap into the stock market without a substantial initial investment. These stocks, typically priced under $5, allow individuals to...
2024-06-14 06:00:13 ET Mark Mahaney from Evercore ISI issued a price target of $75.00 for SHOP on 2024-06-14 04:59:00. The adjusted price target was set to $75.00. At the time of the announcement, SHOP was trading at $64.69. The overall price target consensus is at $86.0...
Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced that Forbes Alexander has been appointed to the Company’s Board of ...
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontli...
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer r...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Eureka Lithium Corp. (CSE: ERKA) (OTCQB: UREKF) (FSE: S580) (" Eureka Lithium " or " Eureka " or the " Company ") announces that it intends to proceed with a share consolidation (the " Consolidation ") of its issued and outstanding...
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results o...
2024-06-14 05:50:00 ET Novo Nordisk 's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping po...
2024-06-14 05:50:00 ET Novo Nordisk 's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping po...
2024-06-14 05:45:00 ET Nvidia has been the talk of the town since generative artificial intelligence (AI) burst onto the scene last year with the advent of OpenAI's ChatGPT. Since then, nearly every tech titan has laid down plans to develop its own version of ChatGPT or other generative...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
58.25%Change Percent:
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
novabay.com Website: